| acetyl-11-keto-beta-boswellic acid | Acetyl-11-keto-beta-boswellic acid is a boswellic acid emphasized in Boswellia standardization discussions. | Limited evidence | Safety evidence: limited human evidence for an AKBA-enriched Boswellia extract, not isolated AKBA. A 90-day trial monitored one extract standardized to 30% AKBA; pregnancy, breastfeeding, surgery, bleeding, liver, kidney, and medication-interaction safety for isolated AKBA remain insufficient. | Standard extract | Read Evidence → |
| acetyl-beta-boswellic acid | Acetylated boswellic acid linked to leukotriene-pathway suppression in Boswellia. | Limited evidence | Boswellia extracts can cause GI upset and may interact with anticoagulants/anti-inflammatory drugs; pregnancy safety is not established. | Standard extract | Read Evidence → |
| bisdemethoxycurcumin | Curcuminoid linked to inflammatory pathway suppression and redox signaling. | Limited evidence | Safety evidence: no adequate isolated-compound human safety profile. Reports involving turmeric or mixed curcuminoids cannot establish bisdemethoxycurcumin-specific adverse effects, contraindications, interactions, pregnancy, breastfeeding, surgery, liver, or kidney guidance. | Standard extract | Read Evidence → |
| Boswellia | Boswellia carries a Grade B rating — moderate evidence. | Moderate evidence | GI upset possible; caution with anticoagulants or anti-inflammatory drugs. | Standard extract | Read Evidence → |
| Boswellia AKBA standardized | Joint function; inflammatory discomfort; safety screen: pregnancy caution; anticoagulants; GI irritation. | Preliminary evidence | Safety evidence: limited short-term human evidence for specific Boswellia extracts. Osteoarthritis trials did not show a clear excess of adverse events, but formulations and reporting varied; pregnancy, breastfeeding, surgery, bleeding, liver, kidney, long-term use, and medication-specific interaction safety remain insufficient. | Standard extract | Read Evidence → |
| Chondroitin | Cartilage-support context; safety screen: warfarin; bleeding disorder; planned surgery. | Preliminary evidence | Use caution with anticoagulants or bleeding-risk contexts. | Standard extract | Read Evidence → |
| Curcumin + piperine | Inflammation markers; bioavailability-enhanced curcumin use; safety screen: drug-interaction sensitive medications; anticoagulants; gallbladder disease. | Preliminary evidence | Safety evidence: turmeric-associated liver injury is uncommon but documented, including recurrence after re-exposure. Piperine altered exposure to a P-glycoprotein substrate in a small human study; medication-specific review is needed, while pregnancy and breastfeeding evidence remain insufficient. | Standard extract | Read Evidence → |
| Curcumin phytosome | Inflammation markers; bioavailable curcumin use; safety screen: anticoagulants; gallbladder disease; surgery window. | Preliminary evidence | Safety evidence: turmeric-associated liver injury is uncommon but documented, including recurrence after re-exposure. Because phytosome products are designed to increase exposure, formulation-specific safety matters; pregnancy, breastfeeding, bleeding, surgery, and medication-interaction evidence for this form remain insufficient. | Standard extract | Read Evidence → |